-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Eledon Pharmaceuticals, Lowers Price Target to $8

Benzinga·11/18/2025 14:10:54
Listen to the news
Guggenheim analyst Vamil Divan maintains Eledon Pharmaceuticals (NASDAQ:ELDN) with a Buy and lowers the price target from $9 to $8.